Review of the clinical research conducted by the consortium for improving survival of lymphoma of the Korean society of hematology lymphoma working party

Cheolwon Suh, Won Seog Kim, Jinseok Kim, Byeong Bae Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The Consortium for Improving Survival of Lymphoma (CISL) in Korean Society of Hematology Lymphoma Working Party had first meeting in February, 2006 with 10 institutions and 12 members. Now CISL comprised of 64 centers. CISL has concentrated research activity on lymphomas which are relatively frequent in Korea and has tried to give favors for the Korean lymphoma patients. CISL has conducted more than 30 retrospective studies to evaluate Korean peculiar lymphoma subtypes. More than 30 prospective trials have been being performed for diffuse large B-cell lymphoma, marginal zone lymphoma, extra-nodal NK/T-cell lymphoma, and so on. The first prospective trial for advanced marginal zone lymphoma has led to use Rituximab containing chemotherapy with the re-imbursement of health insurance in Korea. The multi-center trials of the CISL with new therapeutic modalities will improve further the survival of lymphoma patients not only quantitatively but also qualitatively.

Original languageEnglish
Pages (from-to)171-177
Number of pages7
JournalBlood Research
Volume48
Issue number3
DOIs
Publication statusPublished - 2013 Oct 22

Fingerprint

Hematology
Lymphoma
Survival
Research
Korea
Marginal Zone B-Cell Lymphoma
T-Cell Lymphoma
Health Insurance
Natural Killer Cells
Retrospective Studies
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{27413137f4224e10b397ec2f2dcf3002,
title = "Review of the clinical research conducted by the consortium for improving survival of lymphoma of the Korean society of hematology lymphoma working party",
abstract = "The Consortium for Improving Survival of Lymphoma (CISL) in Korean Society of Hematology Lymphoma Working Party had first meeting in February, 2006 with 10 institutions and 12 members. Now CISL comprised of 64 centers. CISL has concentrated research activity on lymphomas which are relatively frequent in Korea and has tried to give favors for the Korean lymphoma patients. CISL has conducted more than 30 retrospective studies to evaluate Korean peculiar lymphoma subtypes. More than 30 prospective trials have been being performed for diffuse large B-cell lymphoma, marginal zone lymphoma, extra-nodal NK/T-cell lymphoma, and so on. The first prospective trial for advanced marginal zone lymphoma has led to use Rituximab containing chemotherapy with the re-imbursement of health insurance in Korea. The multi-center trials of the CISL with new therapeutic modalities will improve further the survival of lymphoma patients not only quantitatively but also qualitatively.",
author = "Cheolwon Suh and Kim, {Won Seog} and Jinseok Kim and Park, {Byeong Bae}",
year = "2013",
month = "10",
day = "22",
doi = "10.5045/br.2013.48.3.171",
language = "English",
volume = "48",
pages = "171--177",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "3",

}

Review of the clinical research conducted by the consortium for improving survival of lymphoma of the Korean society of hematology lymphoma working party. / Suh, Cheolwon; Kim, Won Seog; Kim, Jinseok; Park, Byeong Bae.

In: Blood Research, Vol. 48, No. 3, 22.10.2013, p. 171-177.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Review of the clinical research conducted by the consortium for improving survival of lymphoma of the Korean society of hematology lymphoma working party

AU - Suh, Cheolwon

AU - Kim, Won Seog

AU - Kim, Jinseok

AU - Park, Byeong Bae

PY - 2013/10/22

Y1 - 2013/10/22

N2 - The Consortium for Improving Survival of Lymphoma (CISL) in Korean Society of Hematology Lymphoma Working Party had first meeting in February, 2006 with 10 institutions and 12 members. Now CISL comprised of 64 centers. CISL has concentrated research activity on lymphomas which are relatively frequent in Korea and has tried to give favors for the Korean lymphoma patients. CISL has conducted more than 30 retrospective studies to evaluate Korean peculiar lymphoma subtypes. More than 30 prospective trials have been being performed for diffuse large B-cell lymphoma, marginal zone lymphoma, extra-nodal NK/T-cell lymphoma, and so on. The first prospective trial for advanced marginal zone lymphoma has led to use Rituximab containing chemotherapy with the re-imbursement of health insurance in Korea. The multi-center trials of the CISL with new therapeutic modalities will improve further the survival of lymphoma patients not only quantitatively but also qualitatively.

AB - The Consortium for Improving Survival of Lymphoma (CISL) in Korean Society of Hematology Lymphoma Working Party had first meeting in February, 2006 with 10 institutions and 12 members. Now CISL comprised of 64 centers. CISL has concentrated research activity on lymphomas which are relatively frequent in Korea and has tried to give favors for the Korean lymphoma patients. CISL has conducted more than 30 retrospective studies to evaluate Korean peculiar lymphoma subtypes. More than 30 prospective trials have been being performed for diffuse large B-cell lymphoma, marginal zone lymphoma, extra-nodal NK/T-cell lymphoma, and so on. The first prospective trial for advanced marginal zone lymphoma has led to use Rituximab containing chemotherapy with the re-imbursement of health insurance in Korea. The multi-center trials of the CISL with new therapeutic modalities will improve further the survival of lymphoma patients not only quantitatively but also qualitatively.

UR - http://www.scopus.com/inward/record.url?scp=84885830937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885830937&partnerID=8YFLogxK

U2 - 10.5045/br.2013.48.3.171

DO - 10.5045/br.2013.48.3.171

M3 - Article

VL - 48

SP - 171

EP - 177

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 3

ER -